brigatinib

Drug Overview

Brigatinib is a highly advanced, prescription cancer medicine. It belongs to a modern family of cancer treatments known as Targeted Therapies or “Smart Drugs.” Unlike older, traditional chemotherapy treatments that attack all fast-growing cells in the body, targeted therapies act like a homing missile. They are designed to seek out and block the specific genetic changes that help certain cancer cells grow and spread.

• Generic Name: Brigatinib
• US Brand Names: Alunbrig
• Drug Class: Tyrosine Kinase Inhibitor (TKI); specifically an ALK Inhibitor
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Fully FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

Brigatinib is a Targeted Therapy designed to fix a broken communication system inside cancer cells. To understand how it works, we have to look at a specific protein called ALK (Anaplastic Lymphoma Kinase).

In some patients with lung cancer, the DNA in the cancer cells becomes scrambled. The ALK gene fuses with another gene, creating a mutated, abnormal protein. You can think of this mutated ALK protein as a broken “ON” switch that is stuck in the ON position. It constantly sends signals down specific cellular pathways (like the STAT3, AKT, and ERK1/2 pathways) telling the cancer cells to grow, divide, and hide from the body’s natural defenses.

At the molecular level, brigatinib works by finding this specific mutated ALK protein and plugging into its energy pocket (the ATP-binding site). By blocking this pocket, the drug physically turns the “ON” switch to “OFF.” Because the cancer cells no longer receive the vital signals telling them to grow and multiply, they stop dividing and eventually die in a natural process called apoptosis. Furthermore, brigatinib is specially designed to cross the blood-brain barrier, allowing it to attack cancer cells that have spread into the brain.

FDA Approved Clinical Indications

Oncological Uses

• Treatment of adult patients with metastatic (advanced) non-small cell lung cancer (NSCLC) that is ALK-positive, as detected by an FDA-approved test.

Non-Oncological Uses

• Currently, there are no FDA-approved non-oncological uses for brigatinib. It is prescribed exclusively for the treatment of cancer.

Dosage and Administration Protocols

Brigatinib is a daily pill that patients can take at home. Because it is an oral tablet, there are no infusion times required. The treatment begins with a lower “step-up” dose to help the lungs adjust to the medication and prevent severe inflammation.

Note: Doses may also be reduced or temporarily paused by your oncologist if you experience severe side effects or if you must take other medications that interact with brigatinib.

Clinical Efficacy and Research Results

Brigatinib has shown exceptional results in long-term clinical trials (such as the ALTA-1L study, with data heavily analyzed between 2020 and 2024). It has become a preferred first-line treatment for ALK-positive lung cancer.

• Disease Progression: In major clinical trials comparing brigatinib to older ALK inhibitors (like crizotinib), brigatinib was far superior. Patients taking brigatinib had a median progression-free survival (the time the cancer is controlled without growing) of approximately 24 months, compared to only 11 months for older drugs.
• Brain Metastases: Lung cancer often spreads to the brain. Research shows brigatinib is highly effective at shrinking these brain tumors, with an intracranial response rate exceeding 70% in newly diagnosed patients.
• Survival Rates: Recent 3-year and 4-year follow-up data show strong overall survival trends, with a large majority of patients living significantly longer, healthier lives compared to those on traditional chemotherapy.

Safety Profile and Side Effects

While brigatinib is highly effective, changing how cell signals work can cause side effects. There is no formal “Black Box Warning” for this medication, but there are serious warnings regarding lung and heart complications.

Common Side Effects (>10%)

• Gastrointestinal Issues: Diarrhea and nausea are very common.
• Fatigue: Feeling unusually tired or lacking energy.
• Cough and Shortness of Breath
• Muscle Pain (Myalgia) and Joint Pain
• Headache
• Skin Rash

Serious Adverse Events

• Interstitial Lung Disease (ILD) / Pneumonitis: Severe, life-threatening inflammation of the lungs. This is most likely to happen in the first 7 days of treatment, which is why the starting dose is lower.
• Hypertension: Dangerously high blood pressure.
• Bradycardia: A very slow heart rate that can cause dizziness or fainting.
• Visual Disturbances: Blurry vision or flashes of light.
• CPK Elevation: Severe muscle breakdown that can eventually damage the kidneys.

Management Strategies

• For Diarrhea: Doctors will recommend over-the-counter anti-diarrheal medicines (like loperamide) and ask you to drink plenty of water.
• For Blood Pressure: You may need to start taking blood pressure medication while on brigatinib to keep your heart healthy.
• For Lung Inflammation: If you develop a sudden, severe cough or trouble breathing, your doctor will stop the drug immediately and may give you steroids to calm your lungs.

Research Areas

While brigatinib is not directly used in stem cell therapy, it is heavily involved in ongoing Regenerative Medicine and Resistance research. Over time, cancer cells can mutate further to outsmart “Smart Drugs” like brigatinib. Researchers are studying how to overcome this resistance. Current clinical trials are exploring combinations of brigatinib with other targeted therapies (like VEGF inhibitors that stop blood vessels from feeding the tumor) to see if cutting off multiple survival pathways at once can keep the cancer in remission permanently, allowing healthy lung tissue more time to heal and regenerate.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

Before starting brigatinib, your healthcare team will ensure it is safe for you by running:

• Genetic Tumor Testing: To confirm the lung cancer is strictly ALK-positive.
• Baseline Blood Tests: Including a Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP) to check liver and kidney function, and CPK levels to check muscle health.
• Vital Signs Check: Recording your baseline blood pressure and heart rate.
• Pregnancy Test: For women of childbearing age, as the drug can harm an unborn baby.

Precautions During Treatment

• Monitor Your Breathing: Pay extremely close attention to any new coughing, wheezing, or trouble breathing, especially during the first week.
• Check Your Blood Pressure: Monitor your blood pressure at home regularly and log the numbers for your doctor.

Do’s and Don’ts

• DO take the medication at the same time every single day to keep a steady amount of the drug in your body.
• DO use highly effective, non-hormonal birth control during treatment and for at least 4 months after the last dose.
• DON’T eat grapefruit or drink grapefruit juice. Grapefruit blocks the liver enzymes that process brigatinib, which can cause toxic levels of the drug to build up in your blood.
• DON’T take any new over-the-counter vitamins, herbal supplements (especially St. John’s Wort), or blood pressure medicines without checking with your oncology pharmacist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Treatment protocols, dosages, and side effects vary by individual. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, treatment options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.